Long Term Effect Of Standardized Dust Mite Allergen Subcutaneous Immunotherapy On Allergic Rhinitis

Objective:To explore the long-term clinical efficacy of standardized dust mite allergen subcutaneous immunotherapy for allergic rhinitis and the relationship between the efficacy and the basic situation of patients.Method:From January 2007 to January 2014,37 patients with allergic rhinitis were diagnosed as dust mite allergy by serum specific IgE detection and skin pricking in our hospital.All patients completed 3 years of standardized dust mite allergen subcutaneous immunotherapy.Before treatment,the basic data(age,gender,disease severity)and symptom scores of patients were counted: nose(itchy nose,sneezing,stuffy nose,runny nose),airway(shortness of breath,wheezing,cough,chest tightness),eyes(itchy eyes,tears,foreign body sensation,red eyes)[ 0-3 points;0 points for no symptoms;1 point for mild symptoms(mild symptoms,easy to bear);2 points for moderate symptoms(obvious symptoms,boring,but can bear);3 points for severe symptoms(symptoms can not bear,affect normal life and / or sleep).After treatment and 5 years follow-up,all patients were scored again.And statistical analysis of the collected data.Because the data do not conform to the normal distribution,Kruskal-Wallis rank sum test is used.Spearman correlation analysis was used for correlation analysis.Result:1.A total of 37 patients completed the treatment,including 20 men and 17 women.Among them,there are 11 people aged 0-20,13 people aged 20-39,10 people aged 40-59,and 3 people over 60.There were 13 patients with mild allergic rhinitis and 24 patients with moderate to severe allergic rhinitis.Before treatment,all patients' symptom scores(median [25 quantiles;75 quantiles])were nose 12 [11.5;12],airway 4 [1;4],eye 4 [1;4],symptom total score 18 [14;20.5];after treatment,symptom scores were nose 8 [6;8],airway 1 [0;4],eye 0 [0;3.5],symptom total score 10 [8;15.5];during follow-up,symptom scores were nose 7 [3.5;12],airway 0;3],eye 0 [0;2],total symptom score 9 [3.5;12].There were significant differences in symptom scores and total symptom scores of nose,lower airway and eyes between before and after treatment and before treatment(P < 0.05).There was no significant difference(P > 0.05)in symptom scores and total symptom scores of nose,airway and eyes between the two groups.2.There was a low correlation between the symptom score of some eyes(before and after treatment,before treatment and during follow-up)and the age(0.5 > or ? 0.3 and P < 0.05).There was no correlation between the difference of other three stages of nose,airway,eye and total symptom score and age(0.3 > |r|or P ? 0.05).3.The difference of symptom score and total symptom score(before treatment,after treatment and after follow-up)in part of nose(before treatment and after treatment)were lower correlated with gender(0.5 > |r| ? 0.3 and P < 0.05).Part of the nose("rhinopruritus" symptoms before treatment than after treatment;"sneeze" symptoms before treatment than after treatment,after treatment than during follow-up;"nasal obstruction" symptoms after treatment than during follow-up),airway("wheezing" symptoms after treatment than during follow-up,"pharyngeal itch" symptoms after treatment than during follow-up,"shortness of breath" symptoms after treatment than during follow-up),eye("photophobia" symptoms after treatment There was a low correlation between the difference of symptom score and gender(0.5 >| r| ? 0.3 and P ? 0.05).There was no correlation between the difference of the other three stages of nose,airway,eye and total score of symptoms and age(0.3 > |r|or P ? 0.05).4.There was a low correlation between the symptom scores and the severity of the disease(0.5 > |r| ? 0.3 and P < 0.05).There was no correlation between the difference of other three stages of nose,airway,eye and total symptom score and the severity of the disease(0.3 > |r|or P ? 0.05).Part of the nose("rhinopruritus" symptoms after treatment compared with follow-up,before treatment compared with follow-up;"sneeze" symptoms after treatment compared with follow-up,before treatment compared with follow-up;"nasal obstruction" symptoms after treatment compared with follow-up;before treatment compared with follow-up),airway("cough" symptoms before treatment compared with after treatment,There was a low correlation between the difference of symptom scores and the severity of the disease(0.5 > 0.3 and P < 0.05).There was a moderate correlation between the difference of symptom score and the severity of the disease(P < 0.05).There was no correlation(0.3 > |r|)or P ? 0.05)between the difference of other three stages of nose,airway,eye and total symptom score and the severity of allergy.Conclusion:1.Standardized dust mite allergen subcutaneous immunotherapy can effectively improve the symptoms of allergic rhinitis,and the therapeutic effect can be obtained after the end of the treatment,and remain stable for a long time.2.Standardized subcutaneous immunotherapy with dust mite allergen can effectively improve the symptoms of patients of all ages,and the therapeutic effect is not related to age.3.The curative effect of standardized hypodermic immunotherapy with dust mite allergen can effectively improve the symptoms of patients of different genders.Although there is a slight difference in the efficacy of different genders at different stages,there is no significant difference in the improvement of the overall symptoms between different genders.4.Standardized subcutaneous immunotherapy with dust mite allergen can effectively improve the symptoms of patients with different disease severity.Although there is a slight difference in the curative effect among patients with different disease severity in some symptoms,there is no significant difference in the improvement of overall symptoms among patients with different disease severity.